Gilead to acquire Myogen
688938
Gilead Sciences Inc. , the  world's third-biggest biotechnology company, said on Monday it  has agreed to acquire Myogen Inc.  for $2.5 billion in  a surprise transaction that gives Gilead access to Myogen's  experimental hypertension drugs.
751178
ZURICH/FRANKFURT  - German drugmaker Merck KGaA   MRCG.DE on Thursday unveiled a surprise 16.6-billion-Swiss   franc ($13.26-billion) deal to buy Swiss biotech firm Serono,   creating a new force in European pharmaceuticals.
34170
LOS ANGELES (CBS.MW) -- Shares of Gilead Sciences climbed Thursday, touching a 52-week high at one point, after the biotechnology firm reported positive results from its recently approved HIV drug Truvada.
644960
It began in July: Mylan Laboratories (nyse: MYL - news - people ) announced it would bid $4 billion in stock for King Pharmaceuticals (nyse: KG - news - people ). Investors were less than unanimously thrilled
113986
The Food and Drug Administration strongly endorsed Biogen Idec Inc.&#39;s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share.
333076
Gilead Sciences Inc. , the world's third-biggest biotechnology company, said on Monday it agreed to acquire Myogen Inc.  for $2.5 billion in a surprise transaction that gives Gilead access to Myogen's experimental hypertension drugs.
614065
By Steve Johnson, San Jose Mercury News, Calif.  Jan. 31--Financially burdened by its purchase in November of two companies, Gilead Sciences of Foster City today reported a net loss of $1.67 billion dollars for the fourth quarter of last year.
607613
Genzyme Corp. said it completed its $345 million acquisition of Bioenvision Inc. despite complaints by some Bioenvision shareholders the price the Cambridge biotech offered was too low. Genzyme initially tried to take control of the New York biotech through a tender offer, but managed to acquire only 22 percent of shares that way. Bioenvision then tried to persuade a majority ...
142092
SAN FRANCISCO (CBS.MW) -- Shares of Elan Corp. and Biogen Idec rose in after-hours trading Tuesday after Tysabri, a drug used for the treatment of multiple sclerosis, was approved by the US Food and Drug Administration.
432855
Biogen Idec in Cambridge is rumored to be in talks to buy or merge with Elan Corp. in Ireland, though the later company denies any such conversation is taking place, Bloomberg News is reporting.
480434
Shares of Elan Corp., Ireland&#39;s biggest drugmaker, rose as much as 7.7 percent after a newspaper reported that the company&#39;s US partner Biogen Idec Inc.
747542
ID Biomedical Corp. (IDB.TO: Quote, Profile, Research) (IDBE.O: Quote, Profile, Research) signed a US distribution deal for its Fluviral drug that could reap sales
287707
Serono SA , one of the world's largest biotechnology companies, was bought yesterday by German chemical giant Merck KGaA in a deal worth more than $13 billion.
351992
In the latest endorsement of a science technique discovered at the University of Massachusetts, the international drug giant Roche signed a $331 million deal with Alnylam Pharmaceuticals Inc. of Cambridge for the rights to develop drugs using RNA interference.
68266
Gilead gets marketing approval for one of its drug candidates.
402032
Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) , a maker of generic drugs, and King Pharmaceutical (KG.N: Quote, Profile, Research) on Wednesday reaffirmed their commitment
723657
Could a jointly marketed drug lead to a joint company? Ireland&#39;s Sunday Tribune said yesterday that US pharmaceuticals company Biogen Idec (nasdaq: BIIB - news - people ) was looking to make an all-stock bid